Greenfield, G., McMullan, R., Robson, N., McGimpsey, J., Catherwood, M., & McMullin, M. F. (2019). Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol.
Citação norma ChicagoGreenfield, Graeme, Ross McMullan, Nuala Robson, Julie McGimpsey, Mark Catherwood, and Mary Frances McMullin. "Response to Imatinib Therapy Is Inferior for E13a2 BCR-ABL1 Transcript Type in Comparison to E14a2 Transcript Type in Chronic Myeloid Leukaemia." BMC Hematol 2019.
Citação norma MLAGreenfield, Graeme, et al. "Response to Imatinib Therapy Is Inferior for E13a2 BCR-ABL1 Transcript Type in Comparison to E14a2 Transcript Type in Chronic Myeloid Leukaemia." BMC Hematol 2019.